Daewon Pharmaceutical Co., Ltd. (003220.KS)
KRW 14020.0
(-1.2%)
KRW 14020.0
(-1.2%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 48.99 Billion | 33.32 Billion | 22.41 Billion | 24.95 Billion | 30.97 Billion | 40.03 Billion |
| Net Income | 23.91 Billion | 30.65 Billion | 6.61 Billion | 17.19 Billion | 26.87 Billion | 23.28 Billion |
| Depreciation & Amortization | 17.56 Billion | 19.36 Billion | 17.8 Billion | 15.67 Billion | 11.81 Billion | 10.39 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -4.61 Billion | -34.11 Billion | -16.78 Billion | -14.34 Billion | -16.83 Billion | -3.85 Billion |
| Other non-cash items | 12.12 Billion | 17.41 Billion | 14.78 Billion | 6.42 Billion | 9.11 Billion | 10.2 Billion |
| Investing Cash Flow | -69.94 Billion | -27.68 Billion | -41.61 Billion | -14.89 Billion | -47.68 Billion | -41.72 Billion |
| Investments in PPE | -21.93 Billion | -13.36 Billion | -11.7 Billion | -15.78 Billion | -36.65 Billion | -42.58 Billion |
| Acquisitions | 225.15 Million | 161.28 Million | -14.6 Billion | -3.62 Billion | -999.98 Million | 1.76 Billion |
| Investment purchases | -52.19 Billion | -17.8 Billion | -23.15 Billion | -6.35 Billion | -12.56 Billion | -4.19 Billion |
| Sales/Maturities of investments | 2.78 Billion | 1.67 Billion | 6.9 Billion | 6.31 Billion | 1.97 Billion | 4.68 Billion |
| Other Investing Activities | 1.16 Billion | 1.64 Billion | 948.91 Million | 4.54 Billion | 556.85 Million | -1.4 Billion |
| Financing Cash Flow | 23.93 Billion | -20.41 Billion | 48.52 Billion | -12.58 Billion | 14.82 Billion | 12.89 Billion |
| Debt repayment | -32.8 Billion | -9.1 Billion | -18.21 Billion | -4.88 Million | -22 Billion | -10 Billion |
| Dividends payments | -7.33 Billion | -4.12 Billion | -3.13 Billion | -5.03 Billion | -4.88 Billion | -4.65 Billion |
| Common Stock Repurchased | -1.62 Billion | -6.17 Billion | -85.84 Million | -5.06 Billion | -37.55 Million | -36.2 Million |
| Common Stock Issuance | 99.82 Million | -11.09 Million | 210.31 Million | -4.88 Million | -4.87 Million | 27.59 Billion |
| Other Financing Activities | 65.59 Billion | -1 Billion | 69.75 Billion | -2.47 Billion | 41.75 Billion | -7.97 Million |
| Accounts receivables | -6.57 Billion | -12.29 Billion | -8.95 Billion | 6.68 Billion | -3.06 Billion | 2.61 Billion |
| Accounts payables | 938.6 Million | 2.1 Billion | -1.44 Billion | 1.55 Billion | 1.9 Billion | 2.65 Billion |
| Inventory | -15.83 Billion | -23.98 Billion | -4.07 Billion | -13.94 Billion | -9.87 Billion | -10.75 Billion |
| Other working capital | 16.85 Billion | 61.52 Million | -2.31 Billion | -8.64 Billion | -5.8 Billion | 6.9 Billion |
| Cash at beginning of period | 26.96 Billion | 41.69 Billion | 10.43 Billion | 13 Billion | 14.88 Billion | 3.67 Billion |
| Cash at end of period | 29.98 Billion | 26.96 Billion | 41.69 Billion | 10.43 Billion | 13 Billion | 14.88 Billion |
| Capital Expenditure | -21.93 Billion | -13.36 Billion | -11.7 Billion | -15.78 Billion | -36.65 Billion | -42.58 Billion |
| Effect of forex changes on cash | 32.08 Million | 45.26 Million | 40.01 Million | -39.13 Million | 3.47 Million | 9.98 Million |
| Net cash flow / Change in cash | 3.01 Billion | -14.72 Billion | 31.25 Billion | -2.56 Billion | -1.88 Billion | 11.21 Billion |
| Free Cash Flow | 27.05 Billion | 19.96 Billion | 10.7 Billion | 9.16 Billion | -5.68 Billion | -2.54 Billion |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -765.4 Million | 9.24 Billion | 23.91 Billion | 749.45 Million | 5.32 Billion | 8 Billion |
| Depreciation & Amortization | 5.33 Billion | 4.13 Billion | 17.56 Billion | 5.67 Billion | 4.29 Billion | 4.19 Billion |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -23.63 Billion | 5.25 Billion | -4.61 Billion | 9.44 Billion | -10.57 Billion | 3 Billion |
| Other non-cash items | 4.49 Billion | -602.08 Million | 12.12 Billion | 7.17 Billion | 1.45 Billion | 2.22 Billion |
| Investing Cash Flow | -14.34 Billion | -4.89 Billion | -69.94 Billion | -32.02 Billion | -10.91 Billion | 668.81 Million |
| Investments in PPE | -5.86 Billion | -4.7 Billion | -21.93 Billion | -9.41 Billion | -6.13 Billion | -2.8 Billion |
| Acquisitions | 44.11 Million | 63.21 Million | 225.15 Million | 23.4 Million | -2.5 Billion | -718.23 Million |
| Investment purchases | -3.43 Billion | -829.11 Million | -52.19 Billion | -39.71 Billion | -15.51 Billion | 9.49 Billion |
| Sales/Maturities of investments | 95.77 Million | 320 Million | 2.78 Billion | 2.59 Billion | -123.17 Million | 699.4 Million |
| Other Investing Activities | -8.47 Billion | 256.86 Million | 1.16 Billion | 14.48 Billion | 13.35 Billion | -6 Billion |
| Financing Cash Flow | 16.1 Billion | 14.86 Billion | 23.93 Billion | 27.14 Billion | 6.39 Billion | -9.36 Billion |
| Debt repayment | -17.13 Billion | -6.82 Billion | -32.8 Billion | -27.46 Billion | -1.93 Billion | -2.31 Billion |
| Dividends payments | -6.35 Billion | - | -7.33 Billion | - | - | -7.33 Billion |
| Common Stock Repurchased | - | - | -1.62 Billion | - | - | - |
| Common Stock Issuance | - | - | 99.82 Million | 99.82 Million | - | - |
| Other Financing Activities | 39.6 Billion | 22.14 Billion | 65.59 Billion | 54.5 Billion | 8.33 Billion | 290.51 Million |
| Accounts receivables | 447.44 Million | 7.23 Billion | -6.57 Billion | -4.53 Billion | -6.53 Billion | -1.51 Billion |
| Accounts payables | -5.1 Billion | 2.83 Billion | 938.6 Million | -4.9 Billion | 5.73 Billion | 1.05 Billion |
| Inventory | -9.06 Billion | 313.84 Million | -15.83 Billion | -11.47 Billion | -2.38 Billion | 1.54 Billion |
| Other working capital | -15.01 Billion | -5.12 Billion | 16.85 Billion | 30.35 Billion | -7.39 Billion | 1.92 Billion |
| Cash at beginning of period | 32.41 Billion | 29.98 Billion | 26.96 Billion | 11.83 Billion | 15.83 Billion | 7.1 Billion |
| Cash at end of period | 19.58 Billion | 32.41 Billion | 29.98 Billion | 29.98 Billion | 11.83 Billion | 15.83 Billion |
| Capital Expenditure | -5.86 Billion | -4.7 Billion | -21.93 Billion | -9.41 Billion | -6.13 Billion | -2.8 Billion |
| Effect of forex changes on cash | -26.59 Million | 110.92 Million | 32.08 Million | -2.84 Million | 26.32 Million | 833.58 Thousand |
| Net cash flow / Change in cash | -12.83 Billion | 2.43 Billion | 3.01 Billion | 18.14 Billion | -4 Billion | 8.73 Billion |
| Free Cash Flow | -20.43 Billion | 15.44 Billion | 27.05 Billion | 13.62 Billion | -5.63 Billion | 14.61 Billion |
HTLFP
300578
SBO
PHYTO
DNN
SGMD